The future of 5-HT1A receptor agonists. (arylpiperazine derivatives)

  title={The future of 5-HT1A receptor agonists. (arylpiperazine derivatives)},
  author={Murasaki Mitsukuni and Miura Sadanori},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
Abstract Mitsukuni Murasaki and Sadanori Miura: The Future of 5-HT1A Receptor Agonists. (Aryl-Piperazine Derivatives) Prog. Neuro- Psychopharmacol-& Biol Psychiat, 1992, 16(6): 833–845. 1. 1. At present the dominant position among anti-anxiety medications has changed from meprobamate to the benzodiazepine derivatives. 2. 2. In order to avoid benzodiazepine's (BZ) undesirable side effects such as impairment of psycho-motor function, memory impairment, low dose dependence and withdrawal symptoms… Expand
13 Citations
Preclinical pharmacology of B-20991, a 5-HT1A receptor agonist with anxiolytic activity.
The results suggest that B-20991 is a 5-HT1A receptor agonist that exhibits anxiolytic activity that causes a dose-related increase in the social interaction and light/dark box behavioral scores. Expand
Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists.
Several iterations of design, synthesis, and testing led to substituted piperidine diphenyl ethers which are potent NRIs with 5-HT1(A) partial agonist properties which exhibit selectivity for NRI over the dopamine (DAT) and serotonin (SERT) reuptake transporters. Expand
Future Prospects for the Pharmacological Treatment of Anxiety
SummaryRecent advances have been made in understanding the neurobiology of fear and anxiety, and elucidating the nature of the neurotransmitters involved in these processes. These findings are, atExpand
Effects of Buspirone, Diazepam, and Zolpidem on Open Field Behavior, and Brain [3H]Muscimol Binding After Buspirone Pretreatment
The present results support the assumption that reduced turnover of 5-HT due to stimulation of5-HT(1A) autoreceptors, may bring about changes in GABA(A) receptor system activity, in some brain structures, leading to the anxiolytic effect. Expand
Overview of serotonin 1A receptor selective agents in anxiety disorders-the developmental situation in Japan
SummarySerotonin 1A receptor selective agents have been developed throughout the world, but have different degrees of acceptance in different countries. Although buspirone has been marketed in theExpand
Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex
The findings show that the effects of acute buspirone on impulsive choice are reversed following chronic treatment and are mediated by 5- HT1A receptors, and suggest, in addition, that the behavioural effects may involve changes in 5-HT functioning in medial prefrontal cortex. Expand
Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.
This system was designed to target the melanocortin receptors (MCRs), with functional group selection based on a known pharmacophore and guidance from molecular modeling to rationally identify positional and stereochemical isomers likely to be active. Expand
Effects of selective serotonergic ligands on posthypoxic audiogenic myoclonus
The data suggest that enhancement of serotonergic activity, particularly through 5‐ HT2 and 5‐HT3 receptors, have therapeutic potential for the treatment of posthypoxic myoclonus in male Sprague‐Dawley rats. Expand
Abstract The phenylpiperazine ring which could not be obtained by reacting aniline derivatives with bis(2-bromoethyl)-N-(ethoxycarbonyl)amine (1a) in a wide spectrum of solvents and temperatures wasExpand
Chemisch neuartige Tranquilizer und Hypnotika
Zur Gruppe der chemisch neuartigen Tranquilizer und Hypnotika konnen derzeit folgende Substanzklassen gezahlt werden: 1. Azaspirodecandione 2. Imidazopyridine und 3. Expand


Serotonergic anxiolytics and treatment of depression.
Clinical findings are consistent with preclinical pharmacology suggesting that 5-HT1A partial agonists may possess intrinsic antidepressant activity and support antidepressant efficacy in addition to anxiolysis. Expand
Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.
Although only wider clinical use for longer periods of time will more clearly define some elements of its pharmacological profile, with its low incidence of sedation buspirone is a useful addition to the treatments available for generalised anxiety. Expand
Buspirone: review of its pharmacology and current perspectives on its mechanism of action.
Buspirone is a novel anxiolytic agent unrelated to the benzodiazepines in structure or pharmacologic properties. Extensive clinical studies have shown buspirone to be effective in the treatment ofExpand
Behavioral and neurochemical studies on the anticonflict actions of buspirone
A series of behavioral and neurochemical studies were performed in order to determine if buspirone (or an active metabolite of this compound) could perturb a component of the γ‐aminobutyricExpand
Benzodiazepines: Anxiety-Reducing Activity by Reduction of Serotonin Turnover in the Brain
The anxiety-reducing activity, and the decrease in serotonin turnover induced by benzodiazepines, were maintained over repeated doses, whereas depressant activity,and the decrease induced in norepinephrine turnover, both rapidly underwent tolerance. Expand
Précis of The neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system
A model of the neuropsychology of anxiety is proposed. The model is based in the first instance upon an analysis of the behavioural effects of the antianxiety drugs (benzodiazepines, barbiturates,Expand
Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone.
There was a significant increase in symptom severity consistent with a withdrawal reaction for the clorazepate group but not the buspirone group, and there was a suggestion that previous discontinuous exposure to benzodiazepines might sensitize patients to subsequent withdrawal effects. Expand
The benzodiazepine story.
  • L. Sternbach
  • Chemistry, Medicine
  • Journal of psychoactive drugs
  • 1983
Valium is a safe, potent anxiolytic with pronounced muscle relaxant properties, and is the best known tranquilizer of its kind. Expand
Habit-Forming Properties of Meprobamate: (Miltown or Equanil)
The increasing demand for meprobamate (Miltown or Equanil) medication by the general public is without parallel in modern pharmacological history and has been the subject of much lay editorialExpand
Dependence on benzodiazepines.
  • M. Lader
  • Medicine
  • The Journal of clinical psychiatry
  • 1983
It is suggested that a definite withdrawal syndrome can supervene on discontinuation of long-term normal doses of benzodiazepines, and the theoretical implications of such normal-dose dependence are discussed. Expand